Come si colloca il rapporto 3320 di PE rispetto ai suoi colleghi?

3320 ha un buon valore in base al suo rapporto Price-To-Earnings ( 8.4 x) rispetto alla media dei peer ( 12.3 x).

Come si colloca il 3320's PE Ratio rispetto ad altre aziende del HK Pharmaceuticals settore?

3320 è costoso in base al suo rapporto Price-To-Earnings ( 8.4 x) rispetto alla media del settore Hong Kong Pharmaceuticals ( 8.4 x).

Qual è il 3320 PE Ratio rispetto al suo Fair PE Ratio? Si tratta del PE Ratio atteso, tenendo conto delle previsioni di crescita degli utili, dei margini di profitto e di altri fattori di rischio della società.

3320 ha un buon valore in base al suo rapporto Price-To-Earnings ( 8.4 x) rispetto al rapporto equo Price-To-Earnings stimato ( 12 x).

Qual è il prezzo equo di 3320 se si considerano i suoi flussi di cassa futuri? Per questa stima utilizziamo un modello di Discounted Cash Flow.

3320 ( HK$5.42 ) viene scambiato al di sotto della nostra stima del [[fair value]] ( HK$20.54 )

Qual è la previsione a 12 mesi degli analisti e abbiamo una qualche fiducia statistica nell'obiettivo di prezzo del consenso?

Il prezzo obiettivo è superiore di oltre 20 % rispetto al prezzo attuale delle azioni, ma gli analisti non sono entro un intervallo di accordo statisticamente attendibile.

China Resources Pharmaceutical Group (SEHK:3320) - Prezzo delle azioni, notizie e analisi

3320 Panoramica delle azioni

3320 analisi fondamentale
Punteggio fiocco di neve
Valutazione	4/6
Crescita futura	2/6
Prestazioni passate	5/6
Salute finanziaria	5/6
Dividendi	3/6

Premi

Negoziato a 73.6% al di sotto della nostra stima del suo valore equo

Si prevede che gli utili cresceranno del 7.46% all'anno

Gli utili sono cresciuti del 11.7% nell'ultimo anno

Analisi del rischio

Ha un alto livello di debito

China Resources Pharmaceutical Group Limited Concorrenti

CSPC Pharmaceutical Group

SEHK:1093

HK$60.4b

Grand Pharmaceutical Group

SEHK:512

HK$16.2b

United Laboratories International Holdings

SEHK:3933

HK$18.1b

Sino Biopharmaceutical

SEHK:1177

HK$59.5b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per China Resources Pharmaceutical Group
Prezzi storici delle azioni
Prezzo attuale dell'azione	HK$5.43
Massimo di 52 settimane	HK$7.11
Minimo di 52 settimane	HK$4.45
Beta	0.42
1Variazione di 1 mese	-7.50%
Variazione a 3 mesi	-1.27%
Variazione di 1 anno	6.68%
3Variazione a 3 anni	56.94%
Variazione a 5 anni	-22.32%
Variazione dall'IPO	-39.73%

Notizie e aggiornamenti recenti

China Resources Pharmaceutical Group Limited's (HKG:3320) Shares Climb 34% But Its Business Is Yet to Catch Up

Oct 07

Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly

Aug 30

Recent updates

China Resources Pharmaceutical Group Limited's (HKG:3320) Shares Climb 34% But Its Business Is Yet to Catch Up

Oct 07

Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly

Aug 30

China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697

Jun 01

Subdued Growth No Barrier To China Resources Pharmaceutical Group Limited (HKG:3320) With Shares Advancing 32%

May 13

China Resources Pharmaceutical Group (HKG:3320) Will Pay A Larger Dividend Than Last Year At CN¥0.1697

Apr 28

China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697

Apr 14

China Resources Pharmaceutical Group's (HKG:3320) Dividend Will Be Increased To CN¥0.1697

Mar 28

China Resources Pharmaceutical Group Limited's (HKG:3320) Shares May Have Run Too Fast Too Soon

Jan 28

We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt

Dec 06

Does China Resources Pharmaceutical Group (HKG:3320) Have A Healthy Balance Sheet?

Sep 07

Does This Valuation Of China Resources Pharmaceutical Group Limited (HKG:3320) Imply Investors Are Overpaying?

Aug 02

With EPS Growth And More, China Resources Pharmaceutical Group (HKG:3320) Makes An Interesting Case

May 26

These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well

May 05

China Resources Pharmaceutical Group's (HKG:3320) Shareholders Will Receive A Bigger Dividend Than Last Year

Apr 04

Is There An Opportunity With China Resources Pharmaceutical Group Limited's (HKG:3320) 24% Undervaluation?

Jan 24

Is China Resources Pharmaceutical Group (HKG:3320) Using Too Much Debt?

Dec 15

China Resources Pharmaceutical Group Limited's (HKG:3320) Intrinsic Value Is Potentially 97% Above Its Share Price

Oct 18

China Resources Pharmaceutical Group (HKG:3320) Takes On Some Risk With Its Use Of Debt

Aug 27

China Resources Pharmaceutical Group (HKG:3320) Has Announced That It Will Be Increasing Its Dividend To HK$0.15

May 29

China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To HK$0.15

May 02

China Resources Pharmaceutical Group's (HKG:3320) Upcoming Dividend Will Be Larger Than Last Year's

Apr 07

China Resources Pharmaceutical Group (HKG:3320) Has A Somewhat Strained Balance Sheet

Mar 31

Are Investors Undervaluing China Resources Pharmaceutical Group Limited (HKG:3320) By 23%?

Feb 21

Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly

Dec 07

China Resources Pharmaceutical Group Limited (HKG:3320) Shares Could Be 32% Below Their Intrinsic Value Estimate

Nov 10

These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well

Aug 29

Is China Resources Pharmaceutical Group Limited (HKG:3320) Trading At A 21% Discount?

Aug 03

Is China Resources Pharmaceutical Group Limited (HKG:3320) A Good Fit For Your Dividend Portfolio?

May 03

Is China Resources Pharmaceutical Group (HKG:3320) A Risky Investment?

Apr 12

Is China Resources Pharmaceutical Group Limited's (HKG:3320) Recent Stock Performance Influenced By Its Fundamentals In Any Way?

Mar 17

Rendimenti per gli azionisti

	3320	HK Pharmaceuticals	HK Mercato
7D	-2.2%	-2.1%	0.05%
1Y	6.7%	-9.4%	11.5%

Ritorno vs Industria: 3320 ha superato il Hong Kong Pharmaceuticals che ha restituito -9.4 % nell'ultimo anno.

Rendimento vs Mercato: 3320 ha avuto una performance inferiore al mercato Hong Kong che ha registrato un rendimento 11.5 % nell'ultimo anno.

Volatilità dei prezzi

Is 3320's price volatile compared to industry and market?
3320 volatility
3320 Average Weekly Movement	6.7%
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	9.0%
10% most volatile stocks in HK Market	18.9%
10% least volatile stocks in HK Market	4.2%

Prezzo delle azioni stabile: 3320 non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 7% ) di 3320 è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2007	72,764	Xiaosong Bai	www.crpharm.com

China Resources Pharmaceutical Group Limited, una holding di investimento, si occupa di ricerca e sviluppo, produzione, distribuzione e vendita al dettaglio di prodotti farmaceutici e altri prodotti sanitari nella Cina continentale e a livello internazionale. Opera attraverso quattro segmenti: Produzione farmaceutica, Distribuzione farmaceutica, Vendita al dettaglio di prodotti farmaceutici e Altri. L'azienda offre una gamma di farmaci chimici, medicinali cinesi e v, nonché prodotti nutrizionali e sanitari per varie aree terapeutiche, tra cui cardiovascolare e cerebrovascolare, tratto alimentare, metabolismo ed endocrino, respiratorio, ortopedia, oncologia, nutrizione medica, gastroenterologia, pediatria, sistema genitourinario, tosse e raffreddore, antinfettivi, dermatologia, soluzioni per infusione, ecc.

China Resources Pharmaceutical Group Limited Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di China Resources Pharmaceutical Group con la sua capitalizzazione di mercato?
3320 statistiche fondamentali
Capitalizzazione di mercato	HK$34.05b
Guadagni(TTM)	HK$4.06b
Ricavi(TTM)	HK$269.22b

8.4x

Rapporto P/E

0.1x

Rapporto P/S

3320 è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
3320 Conto economico (TTM)
Ricavi	CN¥250.48b
Costo del fatturato	CN¥210.97b
Profitto lordo	CN¥39.51b
Altre spese	CN¥35.73b
Guadagni	CN¥3.78b

Ultimi guadagni dichiarati

Jun 30, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	0.60
Margine lordo	15.77%
Margine di profitto netto	1.51%
Rapporto debito/patrimonio netto	77.1%

Come si è comportato 3320 nel lungo periodo?

Vedi performance storica e confronto

Dividendi

3.3%

Rendimento attuale del dividendo

39%

Rapporto di remunerazione

3320 Panoramica delle azioni

Premi

Analisi del rischio

China Resources Pharmaceutical Group Limited Concorrenti

SEHK:1093

HK$60.4b

SEHK:512

HK$16.2b

SEHK:3933

HK$18.1b

SEHK:1177

HK$59.5b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

New minor risk - Dividend sustainability

China Resources Pharmaceutical Group Limited's (HKG:3320) Shares Climb 34% But Its Business Is Yet to Catch Up

Investor sentiment improves as stock rises 18%

Upcoming dividend of HK$0.091 per share

Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly

New minor risk - Financial position

Recent updates

New minor risk - Dividend sustainability

China Resources Pharmaceutical Group Limited's (HKG:3320) Shares Climb 34% But Its Business Is Yet to Catch Up

Investor sentiment improves as stock rises 18%

Upcoming dividend of HK$0.091 per share

Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly

New minor risk - Financial position

First half 2024 earnings released: EPS: CN¥0.41 (vs CN¥0.45 in 1H 2023)

China Resources Pharmaceutical Group Limited Announces Resignation of Bai Xiaosong as Chief Executive Officer

China Resources Pharmaceutical Group Limited to Report First Half, 2024 Results on Aug 29, 2024

China Resources Pharmaceutical Group Limited Announces Directorate Changes

China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697

China Resources Pharmaceutical Group Limited Approves Final Dividend for the Year Ended 31 December 2023

Upcoming dividend of HK$0.17 per share

Subdued Growth No Barrier To China Resources Pharmaceutical Group Limited (HKG:3320) With Shares Advancing 32%

Investor sentiment improves as stock rises 17%

China Resources Pharmaceutical Group (HKG:3320) Will Pay A Larger Dividend Than Last Year At CN¥0.1697

Full year 2023 earnings: EPS and revenues miss analyst expectations

Now 20% overvalued

China Resources Pharmaceutical Group Limited Announces Change of Company Secretary

China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697

China Resources Dong-E-E-Jiao Company Limited Provides Earnings Guidance for the Three Months Ended 31 March 2024

Now 21% overvalued

China Resources Pharmaceutical Group's (HKG:3320) Dividend Will Be Increased To CN¥0.1697

Dividend of HK$0.17 announced

China Resources Pharmaceutical Group Limited, Annual General Meeting, May 30, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

China Resources Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 19 July 2024

China Resources Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

China Resources Pharmaceutical Group Limited's (HKG:3320) Shares May Have Run Too Fast Too Soon

China Resources Pharmaceutical Group Limited Announces Management Changes, Effective on 27 December 2023

We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt

Does China Resources Pharmaceutical Group (HKG:3320) Have A Healthy Balance Sheet?

First half 2023 earnings released: EPS: HK$0.48 (vs HK$0.48 in 1H 2022)

China Resources Pharmaceutical Group Limited to Report First Half, 2023 Results on Aug 31, 2023

Does This Valuation Of China Resources Pharmaceutical Group Limited (HKG:3320) Imply Investors Are Overpaying?

New minor risk - Dividend sustainability

China Resources Pharmaceutical Group Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023

China Resources Pharmaceutical Group Limited Announces Executive Changes

China Resources Pharmaceutical Group Limited Approves to Declare A Final Dividend for the Year Ended 31 December 2022

Upcoming dividend of HK$0.16 per share at 2.1% yield

With EPS Growth And More, China Resources Pharmaceutical Group (HKG:3320) Makes An Interesting Case

Price target increased by 7.6% to HK$7.97

These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well

Price target increased by 8.9% to HK$7.60

China Resources Pharmaceutical Group's (HKG:3320) Shareholders Will Receive A Bigger Dividend Than Last Year

Full year 2022 earnings: EPS and revenues miss analyst expectations

Now 22% undervalued

Now 22% undervalued

China Resources Pharmaceutical Group Limited Announces Appointment of Non-Executive Director

Is There An Opportunity With China Resources Pharmaceutical Group Limited's (HKG:3320) 24% Undervaluation?

Is China Resources Pharmaceutical Group (HKG:3320) Using Too Much Debt?

Less than half of directors are independent

Investor sentiment improved over the past week

China Resources Pharmaceutical Group Limited's (HKG:3320) Intrinsic Value Is Potentially 97% Above Its Share Price

China Resources Pharmaceutical Group (HKG:3320) Takes On Some Risk With Its Use Of Debt

China Resources Pharmaceutical Group Limited Announces Retirement of Mr. Tan Ying as Non-Executive Director

First half 2022 earnings released: EPS: HK$0.48 (vs HK$0.39 in 1H 2021)

China Resources Pharmaceutical Group Limited to Report First Half, 2022 Results on Aug 25, 2022

China Resources Pharmaceutical Group Limited Provides Earnings Guidance for the Six Months Ended 30 June 2022